Effects of the antiparkinsonian drug budipine on central neurotransmitter systems

European Journal of Pharmacology

Volumn 301, Issue 1-3, 1996, Pages 67-73

  Klockgether, Thomas ^a   Wüllner, Ullrich ^a   Steinbach, Joachim Peter ^a   Petersen, Vibke ^b   Turski, Lechoslaw ^c   Löschmann, Peter Andreas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NOVO NORDISK A S   (Denmark)

^c BAYER PHARMA AG   (Germany)

Author keywords

Biperiden; Budipine; Muscarinic; NMDA (N methyl D aspartate); Parkinsonism

Indexed keywords

1 (1 THIENYLCYCLOHEXYL)PIPERIDINE; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; ALPHA AMINO 3 HYDROXY 5 TERT BUTYL 4 ISOXAZOLE PROPIONIC ACID; AMPHETAMINE; ANTIPARKINSON AGENT; APOMORPHINE; BIPERIDEN; BUDIPINE; DOPAMINE; KAINIC ACID; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; PARGYLINE; QUINUCLIDINYL BENZILATE; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICRODIALYSIS; MOUSE; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SEIZURE THRESHOLD; TREMOR;

EID: 17344381219     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00046-5     Document Type: Article

References (26)

1. Eblen, F., P.-A. Löschmann, U. Wüllner, T. Klockgether and J. Dichgans, 1995, A potential role of nitric oxide (NO) in neurodegenerative diseases? Studies with the competitive NO synthase inhibitor 7-nitroindazole, J. Neurol. 242 (Suppl. 2), S71.
2. Giuffra, M.E., V.H. Sethy, T.L. Davis, M.M. Mouradian and T.N. Chase, 1993. Milacemide therapy for Parkinson's disease, Mov. Disord. 8, 47.
3. Honoré, T., S.N. Davies, J. Drejer, E.J. Fletcher, P. Jacobsen, D. Lodge and F.E. Nielsen, 1988, Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists, Science 241, 701.
4. Iizuka, J. and R. Fischer, 1986, Beeinflussung des Parkinson-Tremors durch Budipin. Eine Vergleichsstudie mit Amantadin, Nervenarzt 57, 184.
5. Jackisch, R., H.Y. Huang, W. Reimann and N. Limberger, 1993, Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro, J. Pharmacol. Exp. Ther. 264, 889.
6. Jackisch, R., A. Kruchen, W. Sauermann, G. Hertting and T.J. Feuerstein, 1994, The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists, Eur. J. Pharmacol. 264, 207.
7. Jellinger, K. and H. Bliesath, 1987, Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo, J. Neurol. 234, 280.
8. Klockgether, T. and L. Turski, 1990, NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats, Ann. Neurol. 28, 539.
9. Klockgether, T., P. Jacobsen, P.A. Löschmann and L. Turski, 1993, The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist, J. Neural Transm. Park. Dis. Dement. Sect. 5, 101.
10. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex, Eur. J. Pharmacol. 166, 589.
11. Kornhuber, J., J. Bormann, M. Hubers, K. Rusche and P. Riederer, 1991, Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study, Eur. J. Pharmacol. 206, 297.
12. Löschmann, P.A., K.W. Lange, M. Kunow, K.J. Rettig, P. Jähnig, T. Honore, L. Turski, H. Wachtel, P. Jenner and C.D. Marsden, 1991. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease, J. Neural Transm. Park. Dis. Dement. Sect. 3, 203.
13. Menge, H.G. and U. Brand, 1982, Zusammenfassende Darstellung der Pharmakologie von Budipin, einem neuen 4,4-Diphenylpiperidin-Derivat für die Parkinson-Therapie, Drug Res. 32, 85.
14. Menge, H.G. and U. Brand, 1985, Pharmacologic bases of antiparkinsonian therapy, in: Clinical Experiences with Budipine in Parkinson Therapy, eds. F. Gerstenbrand, W. Poewe and G. Stern (Springer, Berlin), p. 82.
15. Offermeier, J. and J.M. Van Rooyen, 1985, The pharmacodynamics of budipine on central neurotransmitter systems, in: Clinical Experiences with Budipine in Parkinson Therapy, eds. F. Gerstenbrand, W. Poewe and G. Stern (Springer, Berlin), p. 93.
16. Olney, J.W., M.T. Price, J. Labruyere, K.S. Salles, G. Frierdich, M. Mueller and E. Silverman, 1987, Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists, Eur. J. Pharmacol. 142, 319.
17. Paxinos, G. and C. Watson, 1982, The Rat Brain in Stereotaxic Coordinates (Academic Press, Sydney).
18. Porter, R.H.P. and J.T. Greenamyre, 1995, Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential, J. Neurochem. 64, 614.
19. Przuntek, H. and J.-P. Stasch, 1985, Biochemical and pharmacological aspects of the mechanism of action of budipine, in: Clinical Experiences with Budipine in Parkinson Therapy, eds. F. Gerstenbrand, W. Poewe and G. Stern (Springer, Berlin), p. 107.
20. Rabey, J.M., P. Nissipeanu and A.D. Korczyn, 1992, Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease, J. Neural Transm. Park. Dis. Dement. Sect. 4, 277.
21. Schmidt, W.J. and M. Bubser, 1989, Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats, Pharmacol. Biochem. Behav. 32, 621.
22. Schneider, E., P.A. Fischer, R. Clemens, F. Balzereit, E.W. Fünfgeld and H.J. Haase, 1984, Wirkung oraler Memantin-Gaben auf die Parkinson-Syptomatik. Ergebnisse einer placebo-kontrollierten Multicenter-Studie. Dtsch. Med. Wochenschr. 109, 987.
23. Siegfried, J. and R. Fischer, 1985, Budipine: a new chemical substance in the treatment of Parkinson's disease, in: Clinical Experiences with Budipine in Parkinson Therapy, eds. F. Gerstenbrand, W. Poewe and G. Stern (Springer, Berlin), p. 152.
24. Spieker, S., P. Löschmann, C. Jentgens, A. Boose, T. Klockgether and J. Dichgans, 1995. Tremorlytic activity of budipine: a quantitative study with longterm tremor recordings, Clin. Neuropharmacol. 18, 266.
25. Steppuhn, K.G. and L. Turski, 1993, Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants, J. Pharmacol. Exp. Ther. 265, 1063.
26. Zech, K., E. Sturm and G. Ludwig, 1985, Pharmacokinetics and metabolism of budipine in animals and humans, in: Clinical Experiences with Budipine in Parkinson Therapy, eds. F. Gerstenbrand, W. Poewe and G. Stern (Springer, Berlin), p. 113.